Peptide industry news
DELRAY BEACH, Fla., Oct. 7, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Active Pharmaceutical Ingredients (API) Market is projected to reach USD 199.42 billion by 2031 from USD 149.02 billion in 2026, at a CAGR of 6.0% during the forecast period. Browse 747 market data...
Investment advances collaboration on peptide-based products for athletic performance, recovery and longevity TORONTO, Oct. 7, 2026 /PRNewswire/ -- Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced that it has entered into a strategic...
October 7, 2026 · 1 minA surge of consolidation, rising appetite for specialized manufacturing and a shift toward decentralized trials is reshaping Switzerland’s life sciences landscape. From peptide producers to organoid CROs, service providers are scaling and diversifying as global sponsors turn to Swiss hubs for…
October 5, 2026 · 1 minIn this issue: Key themes of CPHI 2026, the GLP-1 manufacturing shift, cold chain logistics, and more.
October 2, 2026 · 1 minUpcoming free, educational webinars from Xtalks will cover topics in clinical trials, commercialization and HEOR, drug safety, food ingredients and innovations, laboratory technology, medical devices, patient recruitment and retention, pharmaceutical manufacturing and supply chain,...
October 1, 2026 · 1 minEstablished CDMO Piramal Pharma Solutions is exhibiting at the forthcoming CPHI Milan 2026. The event will showcase the latest innovations in drug development, manufacturing, supply chains, and biopharma, and will draw tens of thousands of pharmaceutical professionals from around the world.
September 30, 2026 · 1 minThe U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand.
September 16, 2026 · 1 minGLP-1 demand is expanding beyond diabetes into obesity and cardiometabolic care, creating opportunities in oral drugs, next-gen agonists, biosimilars, manufacturing and Asia-Pacific. GLP-1 demand is expanding beyond diabetes into obesity and cardiometabolic care, creating opportunities in oral drugs, next-gen agonists, biosimilars, manufacturing and Asia-Pacific.
September 16, 2026 · 1 minOpportunities lie in integrated partnerships, AI-enabled workflows, disease-relevant models, precision medicine, advanced therapies, and specialized global R&D networks. Opportunities lie in integrated partnerships, AI-enabled workflows, disease-relevant models, precision medicine, advanced therapies, and specialized global R&D networks.
September 15, 2026 · 1 minDr. Jean-Luc Herbeaux appointed Chief Executive Officer of CordenPharma, effective 1 October 2026 Dr. Michael Quirmbach to transition from President & CEO to Board Member and Senior Advisor, remaining actively involved with CordenPharma Planned leadership transition builds on 12 years of...
September 15, 2026 · 1 minContract development and manufacturing organizations looking to do business with biopharmas include Lonza, which has more than 30 sites, and Samsung Biologics, which recently announced a planned acquisition of another CDMO.
September 8, 2026 · 1 minCounterfeit versions of a drug which is still in clinical trials are flooding the black market.
September 4, 2026 · 1 minThe European medicines Agency’s (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may cause loss of vision.
September 4, 2026 · 1 minFDA posted five warning letters dated August 24, 2026 against Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and Tex Peptides for unapproved GLP-1 and related peptides including retatrutide.
September 1, 2026 · 2 minSamsung Biologics' CHF 1.46B ($1.8B) all-cash tender for PolyPeptide at CHF 44.31/share advances with prospectus publication; PolyPeptide posted +42% H1 growth to €236.6M on GLP-1 demand.
August 31, 2026 · 2 minWhat it means when a peptide facility is EDQM-approved: how Certificate of Suitability (CEP) applications work, which peptide APIs hold them, and how buyers should verify one.
August 10, 2026 · 3 minCordenPharma completed its acquisition of AmbioPharm; North Augusta becomes CordenPharma South Carolina and Shanghai becomes CordenPharma Shanghai, creating a ~3,500-person peptide platform.
August 3, 2026 · 1 minAnalysis of FDA warning letters issued to peptide suppliers from 2024 to 2025 reveals consistent patterns in unapproved drug marketing, GMP violations, and the limits of "research use only" disclaimers.
June 14, 2026 · 4 minThe EMA’s first-ever dedicated Guideline on the Development and Manufacture of Synthetic Peptides took effect June 1, 2026. Here is what the document actually requires.
June 14, 2026 · 4 minReal financial data and capacity details for the three biggest peptide CDMOs, plus market sizing and what the capacity crunch means for buyers.
June 14, 2026 · 5 minFDA and EMA have issued updated GMP guidance for peptide drug manufacturers, with new requirements for process validation, impurity control, and quality systems.
June 11, 2026 · 1 minAn estimated $3.1B in reshoring-related peptide manufacturing investment has been announced since January 2025, driven by the BIOSECURE Act and supply chain risk.
June 9, 2026 · 1 minPharmaBlock Sciences opens a 600L SPPS GMP pilot plant at its Zhejiang site, supporting scale-up from R&D to pilot-scale peptide API production.
June 4, 2026 · 1 minFDA expands Import Alert 66-40 to cover 38 foreign peptide API manufacturers across China, India, and South Korea, impacting ~30% of US injectable peptide supply.
May 29, 2026 · 1 minCordenPharma acquires AmbioPharm adding facilities in South Carolina and Shanghai, expanding peptide API manufacturing across three continents.
May 27, 2026 · 1 minHHS Secretary Robert F. Kennedy Jr. announced a key regulatory change that could open doors for the peptide industry.
April 16, 2026 · 3 minUpdates about this directory, its products and partnerships—not independent industry reporting.
Full verification pass over all 386 directory listings: 18 removed for dead, parked, or repurposed domains, 2 tag sets corrected, verification notes added where buyers deserve extra context.
The partnership connects peptide businesses with supplier discovery, fulfillment, cold-chain-aware logistics, and white-label infrastructure.